High level of CA19-9, CA50, and CEA-producible human cholangiocarcinoma cell line changes in the secretion ratios in vitro or in vivo

In Vitro Cellular and Developmental Biology - Animal

Volumn 36, Issue 2, 2000, Pages 104-109

  Watanabe, Michiko ^a,b   Chigusa, Miyoshi ^a   Takahashi, Hiroki ^a   Nakamura, Junta ^a   Tanaka, Hisako ^a   Ohno, Tsuneya ^a  

^a JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Department of Microbiology ^*  (Japan)

Author keywords

CA19 9; CA50; CEA; Cholangiocarcinoma; Established; Production ratio; Tumor markers

Indexed keywords

CA 19-9 ANTIGEN; CA 50 ANTIGEN; CARCINOEMBRYONIC ANTIGEN;

AGED; ANTIGEN DETECTION; ANTIGEN EXPRESSION; ARTICLE; BILE DUCT CARCINOMA; CANCER CELL CULTURE; CASE REPORT; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; TUMOR DIFFERENTIATION;

AGED; ANIMALS; ANTIGENS, TUMOR-ASSOCIATED, CARBOHYDRATE; ASCITIC FLUID; BILE DUCT NEOPLASMS; BILE DUCTS, EXTRAHEPATIC; CA-19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CHOLANGIOCARCINOMA; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL;

MUS MUSCULUS;

EID: 0034105505     PISSN: 10712690     EISSN: None     Source Type: Journal    
DOI: 10.1290/1071-2690(2000)036<0104:HLOCCA>2.3.CO;2     Document Type: Article

References (19)

1. Abelev, G. I. Alpha-fetoprotein as a marker of embryo-specific differentiation normal on human tissue. Transpl. Rev. 20:3-37; 1974.
2. Cascinu, S.; Del Ferro, E.; Barbanti, I.; Ligi, M.; Fedeli, A.; Catalano, G. Tumor markers in the diagnosis of malignant serous effusions. Am. J. Clin. Oncol. 20:247-250; 1997.
3. Del Villano, B. C.; Brennan, S.; Brock, P., et al. Radioimmunometric assay for a monoclonal antibody-defined tumor marker. CA 19-9. Clin. Chem. 29:549-552; 1983.
4. Gold, P.; Freedman, O. Demonstration of tumor specific antigen in human colonic carcinoma by immunologic tolerance and absorption techniques. J. Exp. Med. 127:439-462; 1965.
5. Hagland, C.; Lindgren, J.; Roberts, P. J.; Nordling, S. Difference in tissue expression on tumor markers CA19-9 and CA50 in hepatocellular carcinoma and cholangiocarcinoma. Br. J. Cancer 63:386-389; 1991.
6. Holmgren, J.; Lindholm, L.; Persson, B., et al. Detection by monoclonal antibody of carbohydrate antigen CA50 in serum of patients with carcinoma. Br. Med. J. 288:1479-1482; 1984.
7. Koh, K. K.; In, H. H.; Kim, E. J., et al. New scoring system using tumor markers in diagnosing patients with moderate pericardial effusions. Int. J. Cardiol. 61:5-13; 1997.
8. Koprowski, H.; Steplewski, Z.; Mitchell, K.; Herlyn, M.; Herlyn, D.; Furrer, P. Colorectal carcinoma antigens detected by hybridoma antibodies. Somatic Cell Genet. 5:957-971; 1979.
9. Miyagiwa, M.; Ichida, T.; Tokiwa, T; Sato, J.; Sasaki, H. A new human cholangiocellular carcinoma cell line (HuCC-T1) producing carbohydrate antigen 19/9 in serum-free medium. In Vitro 25:503-510; 1989.
10. Nakamura, S.; Suzuki, S.; Sakaguchi, T.; Seerizawa, A.; Konno, H.; Baba, S.; Baba, S.; Muro, H. Surgical treatment of patients with mixed hepatocellular carcinoma and cholangiocarcinoma. Cancer 78:1671-1676; 1996.
11. Okuda, K.; Ohta, M.; Tsuchiya, Y. The role of ultrasound, percutaneous transhepatic cholangiography, computed tomographic scanning, and magnetic resonance imaging in the preoperative assessment of bile duct cancer. World J. Surg. 12:18-26; 1988.
12. Okuda, K.; Tsuchiya, Y.; Ohta, M. Ultrasound-guided transhepatic pancture in the diagnosis and management of hepatobiliary disorders. In: Popper, H.; Schffner, F., ed. Progress in liver diseases. Vol. 8. New York: Grune & Stratton; 1986:643-658.
13. Pitt, H. A.; Dooley, W. C.; Yeo, C. J.; Cameron, J. L. Malignancies of the biliary tree. Curr. Probl. Surg. 32:1; 1995.
14. Pitt, H. A.; Grochow, L. B.; Abrams, K. A. Cancer of the biliary tree. In: Devita, V. T. Jr.; Hellman, S.; Rosenberg, S. A., ed. Cancer: principles and practice of oncology. Philadelphia, PA: Lippincott-Raven Publishers; 1997:1114-1128.
15. Ramage, J. K.; Donaghy, A.; Farrant, J. M.; Iorns, R.; Williams, R. Serum tumor markers for the diagnosis of cholangiocarcinoma in primary sclerosing cholangiotis. Gastroenterology 108:865-869; 1995.
16. Shimizu, Y.; Demetris, A.; Collin, S. M., et al. Two new human cholangiocarcinoma cell lines and their cytogenetics and responses to growth factors, hormones, cytokines or immunologic effector cells. Int. J. Cancer 52:252-260; 1992.
17. Yamaguchi, K.; Enjoji, M.; Nakayama, F. Cancer of the extrahepatic bile duct: a clinicopathologic study of immuno-histochemistry for CEA, CA19-9, and p21. World J. Surg. 12:11-17; 1988.
18. Yamaguchi, N.; Morioka, H.; Ohkura, H.; Hirohashi, S.; Kawai, K. Establishment and characterization of the human cholangiocarcinoma cell line Hehol-1 in a serum-free, chemically defined medium. J. Natl. Cancer Inst. 75:29-35; 1985.
19. Yano, H.; Ieuma, A.; Haramaki, M.; Momosaki, S.; Ogasawara, S.; Higaki, K.; Kojiro, M. A human combined hepatocellular and cholangio-carcinoma cell line (KMCH-2) that shows the features of hepatocellular carcinoma or cholangiocarcinoma under different conditions. J. Hepatol. 24:413-422; 1996.